Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23 août 2024 18h45 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
22 août 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
09 août 2024 17h59 HE
|
Skye Bioscience, Inc.
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways...
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
24 juil. 2024 06h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
11 juil. 2024 07h15 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
11 juil. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
03 juil. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
01 juil. 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
25 juin 2024 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
10 juin 2024 07h00 HE
|
Skye Bioscience, Inc.
SBI-100 Ophthalmic Emulsion Phase 2a trial does not achieve target product profile; program discontinued Phase 2 study of Nimacimab in obesity expected to start in Q3 2024 Cash runway extended into...